Although approximately 50% of all HER2-positive breast cancers express the steroid receptors estrogen (ER) or progesterone (PR) (luminal B breast cancers), they are usually resistant to endocrine treatment, particularly tamoxifen [48]. Here, ERBB2 is linked to breast carcinoma.